MedPath

Mycophenolic acid

Generic Name
Mycophenolic acid
Brand Names
Myfortic
Drug Type
Small Molecule
Chemical Formula
C17H20O6
CAS Number
24280-93-1
Unique Ingredient Identifier
HU9DX48N0T
Background

Mycophenolic acid is a potent immunosuppressant agent that inhibits de novo purine biosynthesis. It was derived from Penicillium stoloniferum, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative azathioprine due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity. Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until it reaches the small intestine. Mycophenolate mofetil, a prodrug of mycophenolic acid, is also prescribed to transplant recipients to prevent organ rejection.

Indication

Mycophenolic acid is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. Mycophenolic acid is used in combination with cyclosporine and corticosteroids.

Associated Conditions
Kidney Transplant Rejection

New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial

Phase 2
Completed
Conditions
Diabetes Mellitus, Type 1
Interventions
First Posted Date
2004-12-24
Last Posted Date
2020-05-05
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
126
Registration Number
NCT00100178
Locations
🇺🇸

Childrens Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

University of California-San Francisco, San Francisco, California, United States

🇺🇸

Joslin Diabetes Center, Boston, Massachusetts, United States

and more 8 locations

Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma

Phase 2
Terminated
Conditions
Lymphoma
Interventions
Procedure: Extracorporeal Photopheresis
Radiation: Total body irradiation (TBI)
Procedure: Allogeneic bone marrow transplantation
First Posted Date
2003-04-09
Last Posted Date
2023-06-28
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
6
Registration Number
NCT00057954
Locations
🇺🇸

St. Mary - Corwin Regional Medical Center, Pueblo, Colorado, United States

🇺🇸

Tufts-NEMC Cancer Center, Boston, Massachusetts, United States

🇺🇸

Case Comprehensive Cancer Center, Cleveland, Ohio, United States

and more 16 locations

A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients

Phase 3
Completed
Conditions
Kidney Transplantation
Interventions
First Posted Date
2002-10-25
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
539
Registration Number
NCT00048152

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

Phase 2
Completed
Conditions
Graft Rejection
Kidney Transplantation
Renal Transplantation
Interventions
First Posted Date
2002-05-06
Last Posted Date
2014-01-13
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
230
Registration Number
NCT00035555
Locations
🇺🇸

Medical Univ. of South Carolina, Charleston, South Carolina, United States

🇺🇸

Univ. of Nebraska Medical Center, Omaha, Nebraska, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 9 locations
© Copyright 2025. All Rights Reserved by MedPath